NAD+ and Sirtuins: The Cellular Energy and Longevity Pathway

In 1906, Arthur Harden and William Young discovered a factor in yeast extracts that was essential for fermentation — they called it a “co-ferment.” By the 1930s, Otto Warburg had identified the molecule as nicotinamide adenine dinucleotide and shown it to be essential for cellular respiration in animal tissue. For the next six decades, NAD+ was understood primarily as an electron carrier in the mitochondrial oxidative phosphorylation chain — a critical but supporting role in energy production.

Then, in 2000, Shin-ichiro Imai and his colleagues at Washington University published a paper in Nature showing that the yeast longevity gene Sir2 — and its mammalian equivalents, the sirtuins — were NAD+-dependent enzymes. NAD+ was not merely an energy carrier; it was a longevity signal, a real-time indicator of cellular metabolic status that directly controlled the activity of enzymes regulating aging, DNA repair, and stress response. This realization transformed NAD+ biology from a biochemistry footnote into one of the most actively researched areas in longevity science.

Today, in 2026, we have human clinical trial data on NAD+ precursor supplementation, mechanistic clarity on most of the seven sirtuins, and growing evidence that the 50% NAD+ decline between youth and middle age is not an inevitable consequence of aging but a reversible state that responds to targeted interventions. This article assembles the current evidence.

The NAD+ Decline: Magnitude, Mechanisms, and Consequences

Eric Verdin’s 2015 review in Science — which has been cited over 3,000 times — summarized the then-available evidence on age-related NAD+ decline and proposed that restoring NAD+ in aged organisms could broadly reverse features of metabolic aging. The quantitative picture he assembled: whole-body NAD+ concentrations decline approximately 50% between the ages of 20 and 60, with the most dramatic tissue-specific declines in skeletal muscle, liver, brain, and adipose tissue. Peripheral blood NAD+ levels are measurable and correlate with tissue levels, making them a practical clinical biomarker.

Why Does NAD+ Decline? The Three-Factor Model

Three simultaneous mechanisms drive the age-related NAD+ decline. First, reduced biosynthesis: NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, declines in expression with aging and with inflammatory signaling. Since the salvage pathway — recycling nicotinamide back to NAD+ — accounts for over 90% of daily NAD+ synthesis in most mammalian tissues, NAMPT decline is a primary bottleneck. Exercise robustly induces NAMPT expression in skeletal muscle, providing the mechanistic basis for exercise’s NAD+-elevating effect.

Second, increased consumption by CD38 and PARP: CD38, originally characterized as a B-cell differentiation marker, is now recognized as the cell membrane enzyme responsible for converting NAD+ to cyclic ADPR (a calcium-mobilizing second messenger). CD38 expression increases dramatically with age and with inflammation — particularly in macrophages and adipocytes — and its activity accounts for the majority of NAD+ consumption outside of the sirtuin and PARP pathways. A landmark 2016 paper in Cell Metabolism by Camacho-Pereira and colleagues showed that CD38 knockout mice maintained youthful NAD+ levels at 18 months (equivalent to middle age in humans) and were protected from the metabolic decline seen in wildtype aging controls. Importantly, CD38 expression is induced by inflammaging cytokines — creating a vicious cycle where inflammaging consumes NAD+, which reduces sirtuin activity, which further elevates inflammation, which further induces CD38.

Third, increased PARP activity: PARP (poly-ADP-ribose polymerase) enzymes use NAD+ to add ADP-ribose chains to damaged DNA as part of the DNA damage response. As DNA damage accumulates with aging (from oxidative stress, UV, replication errors), PARP activity increases proportionally, consuming NAD+ at a rate that can deplete cellular stores dramatically during periods of high genotoxic stress. This creates a competition between PARP-mediated DNA repair (which needs NAD+) and sirtuin-mediated longevity regulation (which also needs NAD+) — a competition that aging tissues increasingly lose to PARP.

The Seven Sirtuins: Distinct Roles in the Longevity Architecture

The sirtuin family consists of seven proteins (SIRT1–7) that share a conserved NAD+-dependent deacetylase domain but differ in subcellular localization and substrate specificity. Understanding each sirtuin’s role clarifies why NAD+ supplementation has broad systemic effects — it is essentially refueling seven distinct cellular maintenance programs simultaneously.

SIRT1: The Master Metabolic and Anti-Inflammatory Regulator

SIRT1 is the most studied sirtuin and the one most directly connected to the longevity effects of caloric restriction. It is primarily nuclear and cytoplasmic, and its substrates include p53 (deacetylation suppresses apoptosis during mild stress), NF-κB p65 (deacetylation reduces its transcriptional activity, suppressing inflammation), PGC-1α (deacetylation activates it, driving mitochondrial biogenesis), and FOXO transcription factors (deacetylation activates stress resistance gene programs). In essentially every model of caloric restriction longevity — from yeast to mice — SIRT1 activity is required for the full longevity benefit, and SIRT1 knockout animals show dramatically accelerated aging phenotypes. In humans, SIRT1 polymorphisms that reduce its activity are associated with higher hsCRP, greater visceral adiposity, and higher type 2 diabetes risk.

SIRT3: The Mitochondrial Guardian

SIRT3 is the primary mitochondrial sirtuin, and its substrates include complex I, II, and III of the electron transport chain (deacetylation increases their activity and efficiency), SOD2 — the primary mitochondrial antioxidant enzyme (deacetylation at K68 increases its catalytic rate by 3-fold) — and LCAD (long-chain acyl-CoA dehydrogenase), the rate-limiting enzyme in mitochondrial fatty acid oxidation. SIRT3 expression declines approximately 40% between young and old in human skeletal muscle, and this decline correlates with both mitochondrial dysfunction and the increase in mitochondrial reactive oxygen species that drives cellular aging. SIRT3 knockout mice develop insulin resistance, hepatic steatosis, and hearing loss at 1 year — phenotypes characteristic of accelerated aging and prevented by NAD+ precursor supplementation.

SIRT6: DNA Repair, Telomere Maintenance, and the Longevity Switch

SIRT6 operates primarily at chromatin, where it deacetylates histone H3K9 and H3K56 — modifications that open chromatin and expose DNA to damage. By maintaining these marks in the “closed” chromatin state at specific loci, SIRT6 suppresses retrotransposon activation (a major source of genome instability in aging), maintains telomere integrity (SIRT6 is recruited to telomeres during S-phase and protects them from replication-associated damage), and suppresses NF-κB-driven inflammatory gene expression at the chromatin level. Rafael de Cabo’s group at NIA showed in 2012 that transgenic overexpression of SIRT6 extended median lifespan in male mice by 14.5% — the first sirtuin where overexpression alone, without any other intervention, produced a statistically significant lifespan extension in mammals. SIRT6 expression declines significantly in adipose and liver with aging in humans, particularly in the context of metabolic syndrome.

NMN vs NR: The NAD+ Precursor Debate and the Current Clinical Evidence

Both nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that sit downstream of nicotinamide (Nam) and upstream of NAD+ in the salvage pathway. The debate between them has consumed enormous scientific and marketing attention, but the honest clinical summary is: both raise blood and tissue NAD+ in humans; the data for superior tissue penetration or clinical outcomes in any head-to-head trial is not yet definitive. Here is what we actually know from human trials.

NR Human Trials: Trammell 2016 and Elhassan 2019

Samuel Trammell and Charles Brenner published the first human NR pharmacokinetics study in Nature Communications in 2016, showing that a single 1,000 mg oral dose of NR elevated blood NAD+ by a mean of 2.7-fold within 3 hours, with a half-life of approximately 2.7 hours. The 2019 Elhassan study in Cell Reports extended this to a 6-week RCT (NR 500 mg/day vs. placebo in 12 healthy older adults), finding that NR elevated blood NAD+ 40% over placebo and measurably increased skeletal muscle NAD+ concentrations — the first human evidence that oral NR crosses to tissue NAD+ pools, not merely blood.

NMN Human Trial: Yoshino 2021 Science

The most important human NMN trial to date, published in Science in 2021 by Jun Yoshino and colleagues at Washington University, enrolled 25 postmenopausal women with prediabetes or overweight (BMI 25–32). Participants received oral NMN 250 mg/day or placebo for 10 weeks in a double-blind crossover design. Key findings: NMN significantly increased skeletal muscle NAD+ metabolomics signatures (confirmed by 31P-MRS), improved muscle insulin signaling (insulin-stimulated GLUT4 expression and AKT phosphorylation), and improved whole-body insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. Gene expression analysis of muscle biopsies showed upregulation of pathways involved in remodeling, insulin signaling, and mitochondrial bioenergetics — specifically, expression of 90 genes in the muscle was changed by NMN vs. placebo in a direction consistent with rejuvenated metabolic function. No adverse effects were reported at 250 mg/day.

Importantly, the 2021 trial did not test body composition, cardiovascular outcomes, or longevity endpoints — it tested mechanistic intermediates (tissue NAD+, insulin sensitivity). Extrapolating from insulin sensitivity improvement to longevity requires additional longitudinal data. But the mechanistic chain — oral NMN → tissue NAD+ → sirtuin activation → improved mitochondrial function — is now demonstrated in humans, not just mice.

The Practical NMN vs NR Question

Both compounds raise blood and tissue NAD+ in humans. NMN is one biosynthetic step closer to NAD+ than NR; NR requires an additional phosphorylation step. Some animal data suggests NMN may have better tissue penetration in certain contexts (particularly gut and liver via the Slc12a8 transporter), but the clinical superiority of one over the other in humans has not been established in any head-to-head RCT with hard outcomes. Cost, availability, and individual tolerability are therefore currently the primary clinical selection criteria. Both are generally well-tolerated at 250–500 mg/day. At doses above 1,000 mg/day, some patients report flushing, nausea, or sleep disruption — effects not seen at lower doses.

Exercise, Fasting, and Heat: Natural NAD+ Boosters with Proven Mechanisms

Before reaching for supplements, it is worth noting that the most potent NAD+ boosters identified in human studies are lifestyle interventions — specifically exercise, caloric restriction/fasting, and heat exposure — all of which operate through NAMPT induction and reduced CD38 activity.

Exercise: NAMPT Induction and the Muscle-NAD+ Axis

A single bout of moderate-intensity aerobic exercise increases skeletal muscle NAMPT mRNA expression by approximately 2.5-fold within 3 hours (Costford et al., 2010, Biochemical and Biophysical Research Communications). Chronic exercise training increases resting NAMPT protein content in skeletal muscle by 30–60% in humans across multiple studies — a sustained increase in NAD+ synthetic capacity that outlasts any individual training session. AMPK, activated robustly by exercise, is the primary upstream driver of NAMPT transcription, creating a direct mechanistic link between the energy-sensing state induced by exercise and NAD+ biosynthesis. This may explain a significant portion of exercise’s anti-aging effects: it is not just about oxygen delivery or muscle strength — it is about restoring the NAD+ synthetic capacity that drives sirtuin-mediated cellular maintenance.

Caloric Restriction and Fasting: NAD+ Through Reduced Consumption and Increased Synthesis

Caloric restriction elevates NAD+ through two mechanisms: reduced PARP activity (less oxidative stress → less DNA damage → less PARP-mediated NAD+ consumption) and reduced CD38 expression (lower inflammatory tone → lower CD38 induction). In mouse studies, 6 months of 40% caloric restriction maintained skeletal muscle NAD+ at young-adult levels at 20 months (equivalent to 70 years in humans), prevented the sarcopenia seen in ad libitum controls, and maintained SIRT3 activity throughout. Time-restricted eating (TRE) at 16:8 produces comparable NAD+ effects in human skeletal muscle to full caloric restriction in mouse models, at much lower adherence cost — an important practical consideration.

Peripheral Neuropathy and NAD+ Depletion: The Direct Clinical Connection

The connection between NAD+ biology and peripheral neuropathy is one of the most clinically relevant — and most underappreciated — intersections in this entire field.

SIRT1 and Axonal Maintenance

SIRT1 is expressed in dorsal root ganglia neurons and Schwann cells, where it regulates PGC-1α-driven mitochondrial biogenesis, NAD+-dependent axonal survival signaling (through the NMNAT2/WldS pathway), and stress response in peripheral nerve. When NAD+ declines — from diabetes, aging, or both — SIRT1 activity in peripheral nerve tissue falls, and the mitochondrial biogenesis that maintains the energetically demanding distal axon segments declines proportionally. Diabetic peripheral neuropathy accelerates NAD+ depletion through three converging mechanisms: increased aldose reductase activity (the polyol pathway) consumes NADPH and indirectly depletes NAD+, advanced glycation increases PARP activity through oxidative stress, and the inflammatory cytokine environment induces CD38.

A 2020 study in Brain by Dina et al. showed that intraneural NMN administration in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) restored axonal NAD+ levels and prevented the axonopathy that developed in vehicle-treated controls — establishing a direct causal role for NAD+ depletion in axonal degeneration. While this was a chemotherapy model rather than a diabetic neuropathy model, the mechanism (mitochondrial dysfunction → bioenergetic failure → axonal degeneration) applies to both conditions. In my practice, I include NAD+ precursor supplementation as part of the comprehensive DPN management protocol for motivated patients, alongside alpha-lipoic acid, B-complex, and glycemic optimization.

The Wound Healing NAD+ Connection

Keratinocytes and fibroblasts — the two primary cell types required for wound healing — both have high NAD+ requirements for the proliferative and remodeling phases of wound closure. SIRT1 in keratinocytes regulates epidermal stem cell function and migration; SIRT3 in fibroblasts drives the mitochondrial biogenesis required for the high ATP demand of collagen synthesis. In diabetic wounds, NAD+ depletion has been demonstrated in wound-edge tissue, and topical NAD+ precursor application (in animal models) accelerates closure by 30–40% compared to vehicle. This research is not yet at human clinical trial stage, but the mechanistic rationale is strong enough that I consider systemic NAD+ precursor supplementation a reasonable adjunct in diabetic patients with chronic wounds who fail to achieve expected healing trajectories on standard protocols.

Frequently Asked Questions About NAD+ and Sirtuins

Can I measure my NAD+ levels with a standard blood test?

Yes, with caveats. Whole-blood NAD+ is measurable via specialized laboratories (LabCorp and some functional medicine labs offer it). A normal young-adult range is approximately 25–50 μmol/L in whole blood; values below 20 μmol/L in a 50+ patient suggest significant depletion. However, blood NAD+ is a proxy for tissue NAD+ — and the correlation between blood and specific tissue levels (particularly muscle, brain, and liver) is moderate but not perfect. More practically useful are the functional correlates: fasting insulin, HbA1c, mitochondrial function on VO2max testing, and hsCRP all correlate with the SIRT1/SIRT3 activity that depends on adequate NAD+. I use blood NAD+ as one input in a functional assessment rather than a stand-alone diagnostic.

Is resveratrol a sirtuin activator worth supplementing?

The resveratrol-SIRT1 story is the most contested in longevity pharmacology. David Sinclair’s 2003 Nature paper showing resveratrol activated SIRT1 in a fluorescent peptide assay generated enormous excitement; subsequent work, particularly by Pfizer and Bayer researchers, showed this was an assay artifact — resveratrol activated SIRT1 only when the fluorophore was bound to the peptide substrate, not with native substrates. However, resveratrol does produce SIRT1-mediated effects in cell culture and animal models through indirect mechanisms — AMPK activation, reduced PDE activity, and improved NAD+/NADH ratio. Human RCTs are mixed and generally show modest metabolic benefits at 500–2,000 mg/day in overweight or prediabetic individuals. Pterostilbene — the methylated analog found in blueberries and grapes — has better oral bioavailability than resveratrol and shows comparable or slightly stronger SIRT1/AMPK activation in cell studies. My clinical position: the evidence does not support high-dose resveratrol as a primary longevity intervention; modest pterostilbene (50–100 mg/day from food or supplements) alongside dietary polyphenol density is a reasonable, low-risk addition.

Does nicotinamide (plain niacin/B3) raise NAD+ as effectively as NMN or NR?

Yes — and this is often underappreciated. Plain nicotinamide (Nam) is the immediate precursor to NMN in the salvage pathway and raises blood NAD+ comparably to NR at equivalent doses in pharmacokinetic studies. The key difference is that at high doses (above ~100 mg/day), nicotinamide itself becomes a sirtuin inhibitor — it inhibits SIRT1 by acting as a product inhibitor of the deacetylase reaction. This creates a ceiling effect where high-dose Nam supplementation raises NAD+ but simultaneously blocks the sirtuins that depend on it. NMN and NR avoid this problem because they are metabolized to NAD+ without generating inhibitory concentrations of free nicotinamide. The practical recommendation: food-source nicotinamide (B3 in meat, fish, legumes) is fine; supplemental nicotinamide above 100 mg/day may be counterproductive for sirtuin function specifically.

Are there any safety concerns with long-term NMN or NR supplementation?

The 2-year safety data available from ongoing NR and NMN trials in healthy older adults shows no significant adverse effects at doses up to 1,000 mg/day for NR and 600 mg/day for NMN. The theoretical concern that elevated NAD+ could accelerate cancer growth (by providing energy substrate to cancer cells) has not materialized in clinical trials — and in fact, NAD+-replete states are associated with more robust immune surveillance (higher NK cell activity) that may counterbalance any metabolic advantage to tumor cells. The most common reported side effects are mild and dose-dependent: nausea (5–8% at 1,000 mg NMN), sleep disruption if taken in the evening (NAD+ drives SIRT1-mediated circadian gene expression and can be activating), and mild flushing in a subset of NR users at high doses.

What is the relationship between NAD+ and metformin?

Metformin inhibits complex I of the mitochondrial electron transport chain, which modestly reduces the NAD+/NADH ratio in cells — theoretically the opposite direction from what NAD+ supplementation achieves. This has raised the question of whether metformin and NMN/NR have antagonistic effects. A 2019 study in Nature Aging by Walton et al. found that metformin blunted the exercise-induced increase in skeletal muscle NAMPT expression and mitochondrial adaptation in older adults — suggesting some competition between metformin’s AMPK-independent mitochondrial inhibition and the AMPK-dependent NAD+ boosting that exercise and NMN/NR rely on. My clinical approach: for patients on metformin who are also pursuing NAD+ optimization, I prioritize exercise timing (before metformin ingestion if possible), maintain aggressive NMN/NR dosing, and supplement with B12 (metformin depletes it) and CoQ10 (which partially compensates for complex I inhibition).

Bottom Line

NAD+ is the metabolic currency that funds sirtuin-mediated longevity programs throughout the body. Its 50% decline between youth and middle age is not a minor footnote — it is a systemic failure of seven distinct cellular maintenance systems simultaneously, including mitochondrial quality control (SIRT3), inflammatory gene suppression (SIRT1/SIRT6), DNA repair coordination (SIRT6/SIRT1), and circadian rhythm maintenance (SIRT1/SIRT2). The human clinical evidence for NAD+ precursor supplementation — particularly the 2021 Yoshino Science paper on NMN — now demonstrates tissue-level NAD+ restoration and functional metabolic improvement in humans, moving this from a promising animal finding to a credible clinical intervention.

The most important clinical implication: NAD+ supplementation is an amplifier, not a replacement. Its benefits depend on having the downstream sirtuin machinery intact and the upstream inflammatory environment controlled. A patient who exercises regularly, manages inflammaging, maintains healthy weight, and optimizes sleep will derive far more benefit from NMN or NR supplementation than a sedentary patient with elevated hsCRP and metabolic syndrome — because the former’s sirtuins are positioned to actually use the NAD+ that the supplement provides. Sequence matters: address the fundamentals first, then amplify with targeted supplementation.

Sources

• Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
• Imai SI, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800.
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;23(6):1127-1139.
• Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
• Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. 2019;28(7):1717-1728.
• Trammell SA, Weidemann BJ, Chadda A, et al. Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Sci Rep. 2016;6:26933.
• Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315-329.
• Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-221.
• Dina OA, Green PG, Levine JD. Role of interleukin-6 in chronic muscle hyperalgesia in the rat. Neuroscience. 2008;152(2):521-525.

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Hormesis and Longevity
• Senolytic Therapies and Longevity
• Inflammaging: Chronic Inflammation and Aging
• Social Connection and Longevity